Stanisław Góźdź

Stanisław Góźdź

Auto-generated profile, based on publicly available information

Stanisław Góźdź

Collegium Medicum, Jan Kochanowski University, 25-317 Kielce, Poland

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2003 in Mutation Research - Genetic Toxicology and Environmental Mutagenesis
Verified
Journal Article
Closed access
KKKrzysztof Końca
Krzysztof Końca
ALAnna Lankoff
Anna Lankoff
ABAnna Banasik
Anna Banasik
HLHalina Lisowska
Halina Lisowska
TKTomasz Kuszewski
Tomasz Kuszewski
AWAndrzej Wojcik
Andrzej Wojcik

15 March 2004 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
BGBohdan Górski
Bohdan Górski
AJAnna Jakubowska
Anna Jakubowska
THTomasz Huzarski
Tomasz Huzarski
TBTomasz Byrski
Tomasz Byrski
JGJacek Gronwald
Jacek Gronwald
JLJan Lubiński
Jan Lubiński
Three mutations in BRCA1 (5382insC, C61G and 4153delA) are common in Poland and account for the majority of mutations identified to date in Polish breast and breast–ovarian cancer families. It is not known, however, to what extent these 3 founder mutations account for all of the BRCA mutations distributed throughout the country. This question has important implications for health policy and the design of epidemiologic studies. To establish the relative contributions of founder and nonfounder BRCA mutations, we established the entire spectrum of BRCA1 and BRCA2 mutations in a large set of breast–ovarian cancer families with origins in all regions of Poland. We sequenced the entire coding regions of the BRCA1 and BRCA2 genes in 100 Polish families with 3 or more cases of breast cancer and in 100 families with cases of both breast and ovarian cancer. A mutation in BRCA1 or BRCA2 was detected in 66% of breast cancer families and in 63% of breast–ovarian cancer families. Of 129 mutations, 122 (94.6%) were in BRCA1 and 7 (5.4%) were in BRCA2. Of the 122 families with BRCA1 mutations, 119 (97.5%) had a recurrent mutation (i.e., one that was seen in at least 2 families). In particular, 111 families (91.0%) carried one of the 3 common founder mutations. The mutation spectrum was not different between families with and without ovarian cancer. These findings suggest that a rapid and inexpensive assay directed at identifying the 3 common founder mutations will have a sensitivity of 86% compared to a much more costly and labor‐intensive full‐sequence analysis of both genes. This rapid test will facilitate large‐scale national epidemiologic and clinical studies of hereditary breast cancer, potentially including studies of chemoprevention.

21 May 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
TTTomasz Trybek
Tomasz Trybek
AKArtur Kowalik
Artur Kowalik
SGStanisław Góźdź
Stanisław Góźdź
AKAldona Kowalska
Aldona Kowalska
Telomeres are located at the ends of chromosomes and protect them from degradation. Suppressing the activity of telomerase, a telomere‑synthesizing enzyme, and maintaining short telomeres is a protective mechanism against cancer in humans. In most human somatic cells, the expression of telomerase reverse transcriptase (TERT) is repressed and telomerase activity is inhibited. This leads to the progressive shortening of telomeres and inhibition of cell growth in a process called replicative senescence. Most types of primary cancer exhibit telomerase activation, which allows uncontrolled cell proliferation. Previous research indicates that TERT activation also affects cancer development through activities other than the canonical function of mediating telomere elongation. Recent studies have improved the understanding of the structure and function of telomeres and telomerase as well as key mechanisms underlying the activation of TERT and its role in oncogenesis. These advances led to a search for drugs that inhibit telomerase as a target for cancer therapy. The present review article summarizes the organization and function of telomeres, their role in carcinogenesis, and advances in telomerase‑targeted therapy.

1 February 2006 in Toxicology Letters
Verified
Journal Article
Closed access
ALAnna Lankoff
Anna Lankoff
ABAnna Banasik
Anna Banasik
ADAnna Duma
Anna Duma
EOEdyta Ochniak
Edyta Ochniak
HLHalina Lisowska
Halina Lisowska
AWAndrzej Wojcik
Andrzej Wojcik

1 January 2003 in Biological Trace Element Research
Verified
Journal Article
Closed access
PDF file
MKM. Kucharzewski
M. Kucharzewski
JBJ. Braziewicz
J. Braziewicz
UMU. Majewska
U. Majewska
SGS. Gózdz
S. Gózdz

Verified
Journal Article
Open access
PDF file
DBDominika Bębnowska
Dominika Bębnowska
EGEwelina Grywalska
Ewelina Grywalska
Paulina Niedźwiedzka-RystwejPaulina Niedźwiedzka-Rystwej
Paulina Niedźwiedzka-Rystwej
BSBarbara Sosnowska-Pasiarska
Barbara Sosnowska-Pasiarska
JSJolanta Smok-Kalwat
Jolanta Smok-Kalwat
Wojciech PolkowskiWojciech Polkowski
Wojciech Polkowski
Gastric cancer (GC) is one of the most commonly diagnosed malignancies and, unfortunately, still has a high mortality rate. Recent research points to CAR-T immunotherapy as a promising treatment for this disease. Using genetically engineered T cells designed to target a previously selected antigen, researchers are able to harness the natural anti-tumor activity of T cells. For therapy to be successful, however, it is essential to choose antigens that are present on tumor cells but not on healthy cells. In this review, we present an overview of the most important targets for CAR-T therapy in the context of GC, including their biologic function and therapeutic application. A number of clinical studies point to the following as important markers in GC: human epidermal growth factor receptor 2, carcinoembryonic antigen, mucin 1, epithelial cell adhesion molecule, claudin 18.2, mesothelin, natural-killer receptor group 2 member D, and folate receptor 1. Although these markers have been met with some success, the search for new and improved targets continues. Key among these novel biomarkers are the B7H6 ligand, actin-related protein 2/3 (ARP 2/3), neuropilin-1 (NRP-1), desmocollin 2 (DSC2), anion exchanger 1 (AF1), and cancer-related antigens CA-72-4 and CA-19-9.